Details of the Drug Therapeutic Target (DTT)

General Information of Drug Therapeutic Target (DTT) (ID: TT8S9AV)

• DTT Name: Lymphocyte antigen 96 (LY96)
• Synonyms: MD-2 protein; MD-2; LY96; ESOP-1
• Gene Name: LY96
• DTT Type: Literature-reported target; [1]
• UniProt ID: LY96_HUMAN
• TTD ID: T52382
• Sequence:
  MLPFLFFSTLFSSIFTEAQKQYWVCNSSDASISYTYCDKMQYPISINVNPCIELKRSKGL
  LHIFYIPRRDLKQLYFNLYITVNTMNLPKRKEVICRGSDDDYSFCRALKGETVNTTISFS
  FKGIKFSKGKYKCVVEAISGSPEEMLFCLEFVILHQPNSN
• Function: Cooperates with TLR4 in the innate immune response to bacterial lipopolysaccharide (LPS), and with TLR2 in the response to cell wall components from Gram-positive and Gram-negative bacteria. Enhances TLR4-dependent activation of NF-kappa-B. Cells expressing both MD2 and TLR4, but not TLR4 alone, respond to LPS.
• KEGG Pathway:
  NF-kappa B signaling pathway (hsa04064)
  Toll-like receptor signaling pathway (hsa04620)
  Pathogenic Escherichia coli infection (hsa05130)
  Pertussis (hsa05133)
  Toxoplasmosis (hsa05145)
• Reactome Pathway:
  Toll Like Receptor 4 (TLR4) Cascade (R-HSA-166016)
  MyD88 (R-HSA-166058)
  MyD88-independent TLR3/TLR4 cascade (R-HSA-166166)
  TRIF-mediated programmed cell death (R-HSA-2562578)
  MyD88 deficiency (TLR2/4) (R-HSA-5602498)
  IRAK4 deficiency (TLR2/4) (R-HSA-5603041)
  Activation of IRF3/IRF7 mediated by TBK1/IKK epsilon (R-HSA-936964)
  IKK complex recruitment mediated by RIP1 (R-HSA-937041)
  TRAF6 mediated induction of TAK1 complex (R-HSA-937072)
  Ligand-dependent caspase activation (R-HSA-140534)

Molecular Interaction Atlas (MIA) of This DTT

3 Investigative Drug(s) Targeting This DTT

Drug Name	Drug ID	Indication	ICD 11	Highest Status	REF
3-Hydroxy-Myristic Acid	DMFJLWO	Discovery agent	N.A.	Investigative	[1]
Lauric Acid	DM9C8KQ	Discovery agent	N.A.	Investigative	[1]
MYRISTIC ACID	DMYX0BL	Discovery agent	N.A.	Investigative	[2]

References

• [1] How many drug targets are there Nat Rev Drug Discov. 2006 Dec;5(12):993-6.
• [2] The Protein Data Bank. Nucleic Acids Res. 2000 Jan 1;28(1):235-42.